

Sun Young Rha

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3598679/sun-young-rha-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

383
papers

11,322
citations

46
h-index

93
g-index

400
ext. papers

13,140
ext. citations

4.8
avg, IF

5.75
L-index

#	Paper	IF	Citations
383	The Essentials of Multiomics.. <i>Oncologist</i> , 2022 , 27, 272-284	5.7	2
382	Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 351-351	2.2	
381	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 330-330	2.2	
380	Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).. <i>Gastric Cancer</i> , 2022 , 1	7.6	1
379	First data for sotorasib in patients with pancreatic cancer with KRAS p.G12C mutation: A phase I/II study evaluating efficacy and safety. <i>Journal of Clinical Oncology</i> , 2022 , 40, 360490-360490	2.2	6
378	Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study. <i>Cancer Research</i> , 2022 , 82, P2-13-07-P2-13-07	10.1	2
377	Self-efficacy for coping with cancer and quality of life in advanced gastric cancer patients.. <i>European Journal of Oncology Nursing</i> , 2022 , 58, 102120	2.8	0
376	Fear of cancer recurrence and its predictors and outcomes among cancer survivors: A descriptive correlational study.. <i>European Journal of Oncology Nursing</i> , 2022 , 58, 102138	2.8	
375	Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021 , 44, 1387-1403	7.2	0
374	Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer. <i>Cancer Medicine</i> , 2021 , 10, 8365-8376	4.8	2
373	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021 , 39, 1366-1374	4.3	2
372	Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea. <i>Cancer Research and Treatment</i> , 2021 , 53, 323-329	5.2	6
371	Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11516-11516	2.2	1
370	Multi-omics characterization of left-right colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3542-3542		
369	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , 2021 , 10, 3249-3260	4.8	0
368	Value of cabozantinib in the treatment of advanced metastatic clear cell renal cell carcinoma (ccRCC): Real-world data from a single Korean institution.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16578-e16578	2.2	2
367	Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4056-4056	2.2	1

366	Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4063-4063	2.2	0
365	Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population. <i>Gut</i> , 2021 , 70, 829-837	19.2	27
364	Stable Symptom Clusters and Evolving Symptom Networks in Relation to Chemotherapy Cycles. <i>Journal of Pain and Symptom Management</i> , 2021 , 61, 544-554	4.8	3
363	p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer. <i>Biochemical Pharmacology</i> , 2021 , 183, 114320	6	2
362	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. <i>Gastric Cancer</i> , 2021 , 24, 589-601	7.6	6
361	Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2021 , 144, 49-60	7.5	7
360	Development and validation of a targeted sequencing panel for application to treatment-refractory solid tumor.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 245-245	2.2	0
359	Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16). <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211042812	5.4	1
358	"3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. <i>Cancer Research</i> , 2021 , 81, 2788-2798	10.1	3
357	Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. <i>Gut</i> , 2021 ,	19.2	3
356	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2903-2913	2.2	24
355	Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. <i>Oncologist</i> , 2021 , 26, e1704-e1729	5.7	4
354	Early Tumor-Immune Microenvironmental Remodeling and Response to Frontline Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer.. <i>Cancer Discovery</i> , 2021 ,	24.4	4
353	Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2418-2426	2.2	33
352	Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3081-3081	2.2	13
351	Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3590-3590	2.2	3
350	First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4534-4534	2.2	4
349	Safety and preliminary antitumor activity of the transforming growth factor beta (TGF- β) receptor I kinase inhibitor, vactosertib, in combination with paclitaxel in patients with metastatic gastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e16505-e16505	2.2	2

348	Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells. <i>Yonsei Medical Journal</i> , 2020 , 61, 587-596	3	3
347	An open-label, phase I trial of BI 754091 alone and in combination with BI 754111 in Asian patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3054-3054	2.2	1
346	Diagnostic accuracy of CT-staging of advanced gastric cancer following neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4551-4551	2.2	
345	An open-label, multicenter, phase II study of ceritinib in patients with advanced ALK+ non-lung solid tumors and hematological malignancies (ASCEND-10).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3520-3520	3.3	20
344	Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells. <i>Genomics and Informatics</i> , 2020 , 18, e37	1.9	1
343	Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma. <i>Diagnostics</i> , 2020 , 10,	3.8	4
342	Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020 , 18, 587-601	6.4	14
341	Gene Expression Profiling Identifies Akt as a Target for Radiosensitization in Gastric Cancer Cells. <i>Frontiers in Oncology</i> , 2020 , 10, 562284	5.3	
340	Cross-species chromatin interactions drive transcriptional rewiring in Epstein-Barr virus-positive gastric adenocarcinoma. <i>Nature Genetics</i> , 2020 , 52, 919-930	36.3	26
339	Development and evaluation of the Cancer Symptom Management System: Symptom Management Improves your LiFE (SMILE)-a randomized controlled trial. <i>Supportive Care in Cancer</i> , 2020 , 28, 713-723	3.9	3
338	Unmet needs in the physical and daily living domain mediates the influence of symptom experience on the quality of life of gastric cancer patients. <i>Supportive Care in Cancer</i> , 2020 , 28, 1419-1431	3.9	9
337	Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing. <i>Frontiers in Pharmacology</i> , 2020 , 11, 608774	5.6	3
336	Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer 2019 , 7, 268		14
335	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019 , 15, 929-941	3.6	23
334	EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. <i>BMC Cancer</i> , 2019 , 19, 494	4.8	39
333	Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 1153-1163	14	
332	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <i>Cancer Research and Treatment</i> , 2019 , 51, 1-11	5.2	13
331	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019 , 112, 20-28	7.5	0

330	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 1206-1214	7.6	17
329	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial 2019 , 7, 30		43
328	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 113-122	7.6	13
327	Stability of symptom clusters and sentinel symptoms during the first two cycles of adjuvant chemotherapy. <i>Supportive Care in Cancer</i> , 2019 , 27, 1687-1695	3.9	5
326	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , 2019 , 140, 143-149	5.3	3
325	Prospective validation of a serum miRNA panel for early detection of gastric cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4065-4065	2.2	1
324	Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured Using 18 F-FDG PET/CT in Locally Advanced and Metastatic Gallbladder Carcinoma. <i>Yonsei Medical Journal</i> , 2019 , 60, 604-610	3	11
323	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019 , 51, 211-222	5.2	5
322	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019 , 51, 819-831	5.2	8
321	Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea. <i>Cancer Research and Treatment</i> , 2019 , 51, 1380-1391	5.2	11
320	Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019 , 51, 851-860	5.2	8
319	T-cell-inflamed gene expression profile (GEP) and PD-L1 expression in patients (pts) with esophageal cancer (EC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 26-26	2.2	3
318	Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. <i>Cancer Research and Treatment</i> , 2019 , 51, 1578-1588	5.2	1
317	Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer. <i>Oncologist</i> , 2019 , 24, e1108-e1114	5.7	9
316	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019 , 2, 643-648	6.7	19
315	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function 2019 , 7, 339		25
314	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. <i>Oncology</i> , 2019 , 96, 59-69	3.6	9
313	Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. <i>Gastric Cancer</i> , 2018 , 21, 802-810	7.6	7

312	Rab25 augments cancer cell invasiveness through a β 1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. <i>Experimental and Molecular Medicine</i> , 2018 , 50, e435	12.8	26
311	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). <i>Gastric Cancer</i> , 2018 , 21, 819-830	7.6	15
310	Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor. <i>International Journal of Cancer</i> , 2018 , 143, 151-159	7.5	16
309	Screening audits as a quality assurance tool in good clinical practice compliant research environments. <i>BMC Medical Ethics</i> , 2018 , 19, 30	2.9	1
308	The prognostic value of volume-based parameters using F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018 , 21, 213-224	7.6	14
307	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. <i>Annals of Surgical Oncology</i> , 2018 , 25, 3222-3230	3.1	40
306	Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 5272-5281	12.9	13
305	Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 69	22.4	20
304	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , 2018 , 18, 158	4.8	12
303	A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4510-4510	2.2	5
302	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 581-581	2.2	3
301	A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS707-TPS707	2.2	2
300	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Korean Journal of Internal Medicine</i> , 2018 , 33, 383-390	2.5	7
299	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <i>Cancer Research and Treatment</i> , 2018 , 50, 488-494	5.2	20
298	Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. <i>Cancer Research and Treatment</i> , 2018 , 50, 1378-1387	5.2	8
297	A Prediction Model of Tumor Progression and Survival in HER2 Positive Metastatic Gastric Cancer Patients treated with Trastuzumab and Chemotherapy. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, SY31-2	0	
296	Real-world first-line advanced gastric cancer in western and Asian countries: Treatment patterns and impact on quality of life (QOL).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16018-e16018	2.2	
295	The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control. <i>Cancer Nursing</i> , 2018 , 41, E49-E57	2.6	

294	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , 2018 , 18, 1116	4.8	31
293	Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. <i>Anticancer Research</i> , 2018 , 38, 6171-6180	2.3	7
292	Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition. <i>Cancers</i> , 2018 , 10,	6.6	11
291	Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 5899-5908	5.6	3
290	Reconsideration of sample size and power calculation for overall survival in cancer clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2018 , 12, 90-91	1.8	0
289	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	11
288	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 663-669	8.7	48
287	CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. <i>Yonsei Medical Journal</i> , 2018 , 59, 588-594	3	18
286	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. <i>AAPS Journal</i> , 2018 , 20, 72	3.7	
285	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. <i>Annals of Surgery</i> , 2017 , 265, 946-953	7.8	84
284	ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. <i>Biochemical Pharmacology</i> , 2017 , 123, 73-84	6	2
283	Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life. <i>Supportive Care in Cancer</i> , 2017 , 25, 1519-1527	3.9	26
282	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. <i>Apmis</i> , 2017 , 125, 223-229	3.4	7
281	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 773-781	4.3	4
280	Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines. <i>Biochemical Pharmacology</i> , 2017 , 138, 163-173	6	8
279	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017 , 6, 902-909	4.0	28
278	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. <i>Cancer Discovery</i> , 2017 , 7, 630-651	24.4	34
277	Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017 , 18, 1637-1651	21.7	174

276	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , 2017 , 8, 61837-61845	10
275	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. <i>Oncology Letters</i> , 2017 , 14, 2385-2392	2.6 5
274	A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017 , 23, 5981-5992	12.9 73
273	Prevalence and prognostic implications of psychological distress in patients with gastric cancer. <i>BMC Cancer</i> , 2017 , 17, 283	4.8 56
272	A phase IB study of CX-4945 in combination with gemcitabine plus cisplatin in the frontline systemic treatment of patients with advanced cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 294-294	2.2 3
271	Microarray-based tumor molecular profiling to direct choice of cisplatin plus S-1 or oxaliplatin plus S-1 for advanced gastric cancer: A multicentre, prospective, proof-of-concept phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 48-48	2.2 4
270	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. <i>Oncotarget</i> , 2017 , 8, 31169-31179	3.3 8
269	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017 , 8, 38389-38398	3.3 26
268	PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. <i>Oncotarget</i> , 2017 , 8, 113494-113501	3.3 26
267	Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. <i>American Journal of Cancer Research</i> , 2017 , 7, 134-138	4.4 6
266	PD-L1 expression in patients with metastatic gastric cancer in South Korea.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1571-1571	2.2 1
265	A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. <i>Journal of Physical Education and Sports Management</i> , 2016 , 2, a000992	2.8 11
264	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 2051-9	4.9 9
263	Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. <i>Nature Communications</i> , 2016 , 7, 12983	17.4 78
262	Assessment of Adrenal Function and Health-Related Quality of Life in Advanced Gastric Cancer Patients Who Received First-Line Chemotherapy. <i>Oncology</i> , 2016 , 90, 248-54	3.6 2
261	Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. <i>Supportive Care in Cancer</i> , 2016 , 24, 4559-66	3.9 3
260	Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2728-35	2.2 138
259	Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 507-16	2.8 9

258	Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1002-1011	4.3	40
257	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1629-37	4.0	445
256	Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016 , 30, 279-86	2.5	9
255	Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference. <i>Gastric Cancer</i> , 2016 , 19, 15-20	7.6	36
254	Epstein-Barr virus BARP1-induced NFB/miR-146a/SMAD4 alterations in stomach cancer cells. <i>Oncotarget</i> , 2016 , 7, 82213-82227	3.3	27
253	Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. <i>Oncotarget</i> , 2016 , 7, 72099-72112	3.3	11
252	Regulation of the epithelial to mesenchymal transition and metastasis by Raf kinase inhibitory protein-dependent Notch1 activity. <i>Oncotarget</i> , 2016 , 7, 4632-46	3.3	18
251	Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. <i>Oncotarget</i> , 2016 , 7, 24549-58	3.3	7
250	p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016 , 48, 208-15	5.2	9
249	Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. <i>Cancer Research and Treatment</i> , 2016 , 48, 1286-1292	5.2	4
248	Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 503-503	2.2	
247	Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis. <i>Journal of Cancer</i> , 2016 , 7, 1550-6	4.5	13
246	Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma. <i>Yonsei Medical Journal</i> , 2016 , 57, 831-9	3	11
245	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , 2016 , 7, 1174-80	4.5	22
244	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016 , 48, 553-60	5.2	13
243	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , 2016 , 7, 44608-44620	3.3	31
242	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016 , 7, 8055-66	3.3	28
241	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. <i>JCI Insight</i> , 2016 , 1, e87607	9.9	32

240	PTEN Methylation Dependent Sinonasal Mucosal Melanoma. <i>Cancer Research and Treatment</i> , 2016 , 48, 853-8	5.2	4
239	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , 2016 , 263, 96-102	7.8	43
238	Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. <i>BMC Cancer</i> , 2016 , 16, 385	4.8	37
237	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016 , 16, 434	4.8	93
236	Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. <i>Supportive Care in Cancer</i> , 2016 , 24, 3379-89	3.9	12
235	Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. <i>Journal of Surgical Oncology</i> , 2016 , 114, 859-864	2.8	10
234	Cranofacial osteosarcoma: Single institutional experience in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12, e149-53	1.9	10
233	The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 3938-45	3.1	9
232	Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer. <i>Gastric Cancer</i> , 2015 , 18, 824-32	7.6	77
231	Caregiving burden and health-promoting behaviors among the family caregivers of cancer patients. <i>European Journal of Oncology Nursing</i> , 2015 , 19, 174-81	2.8	39
230	Caregiving burden and the quality of life of family caregivers of cancer patients: the relationship and correlates. <i>European Journal of Oncology Nursing</i> , 2015 , 19, 376-82	2.8	85
229	Clinicopathological features and prognostic significance of HER2 expression in gastric cancer. <i>Oncology</i> , 2015 , 88, 147-56	3.6	14
228	PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer. <i>Oncology</i> , 2015 , 88, 76-85	3.6	24
227	Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 397-408	3.5	27
226	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015 , 15, 154	4.8	46
225	Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. <i>International Journal of Clinical Oncology</i> , 2015 , 20, 1226-32	4.2	7
224	PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015 , 136, 2273-83	7.5	9
223	Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 224-31	3.1	38

222	Prevalence of human papillomavirus infection and RAS mutation in sporadic keratoacanthoma. <i>International Journal of Dermatology</i> , 2015 , 54, e453-7	1.7	0
221	Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation. <i>Journal of Dermatology</i> , 2015 , 42, 881-8	1.6	8
220	Current Strategy of Chemotherapy for Bone Tumors. <i>The Journal of the Korean Orthopaedic Association</i> , 2015 , 50, 438	0.1	
219	Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report. <i>Yonsei Medical Journal</i> , 2015 , 56, 503-9	3	28
218	Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10. <i>Gynecologic Oncology</i> , 2015 , 136, 212-7	4.9	4
217	Upregulated, 7q21-22 amplicon candidate gene SHFM1 confers oncogenic advantage by suppressing p53 function in gastric cancer. <i>Cellular Signalling</i> , 2015 , 27, 1075-86	4.9	8
216	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015 , 64, 1721-31	19.2	137
215	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 2015 , 47, 9-17	5.2	7
214	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10565-10565	2.2	5
213	INTEGRATE: A randomized, phase II, double-blind, placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC): A study by the Australasian Gastrointestinal Trials Group (AGITG) Final overall and subgroup results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4003-4003	2.2	8
212	A serum microRNA biomarker panel for detection of gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4060-4060	2.2	2
211	Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4554-4554	2.2	4
210	INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9-9	2.2	6
209	Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 464-464	2.2	1
208	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. <i>American Journal of Cancer Research</i> , 2015 , 5, 72-86	4.4	10
207	Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. <i>World Journal of Gastroenterology</i> , 2015 , 21, 2711-8	5.6	19
206	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015 , 47, 781-9	5.2	7
205	Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study. <i>Intestinal Research</i> , 2015 , 13, 274-81	4.1	3

204	Do all patients with HER2-positive gastric/GEJ cancer benefit from trastuzumab?. <i>Journal of Clinical Oncology</i> , 2015 , 33, 185-185	2.2	
203	Retrospective analysis of chemotherapy for the patients with advanced bladder adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 399-399	2.2	
202	Modeling post-progression survival in patients with HER2-positive metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15020-e15020	2.2	
201	A phase III study to compare efficacy and safety of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with metastatic or recurrent gastric cancer after failure of first-line chemotherapy (DREAM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4138-TPS4138	2.2	
200	Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4558-4558	2.2	
199	Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4113-4113	2.2	
198	The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. <i>Molecular Cancer Research</i> , 2014 , 12, 228-38	6.6	53
197	Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2765-72	2.2	289
196	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , 2014 , 12, 232	3.4	27
195	Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014 , 66, 704-10	10.2	282
194	First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 335-40	3.3	7
193	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e127-31	3.3	20
192	Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency. <i>European Journal of Cancer</i> , 2014 , 50, 746-52	7.5	17
191	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 286-96	21.7	215
190	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014 , 44, 5-16	4.4	30
189	Kaposi's Varicelliform-Like Eruption in a Patient Treated with Everolimus for Metastatic Renal Cell Carcinoma: Report of a Rare Case. <i>Case Reports in Oncology</i> , 2014 , 7, 337-42	1	3
188	Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study. <i>Oncology</i> , 2014 , 86, 329-35	3.6	
187	Comparison of Melanoma Subtypes among Korean Patients by Morphologic Features and Ultraviolet Exposure. <i>Annals of Dermatology</i> , 2014 , 26, 485-90	0.4	15

186	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 799-808	3.5	6
185	A case of gingival candidiasis with bone destruction on gastric cancer patient receiving cytotoxic chemotherapy. <i>Case Reports in Oncological Medicine</i> , 2014 , 2014, 145394	0.9	1
184	Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. <i>Journal of Clinical Pathology</i> , 2014 , 67, 33-9	3.9	11
183	Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. <i>Pathology</i> , 2014 , 46, 316-24	1.6	15
182	The effect of disintegrin-metalloproteinase ADAM9 in gastric cancer progression. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3074-85	6.1	30
181	Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. <i>Magnetic Resonance in Medicine</i> , 2014 , 71, 1554-8	4.4	96
180	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4576-4576	2.2	2
179	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 396-396	2.2	7
178	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 398-398	2.2	6
177	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway targeted therapy and one prior mTOR inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 473-473	2.2	1
176	Ifosfamide-induced Fanconi syndrome with diabetes insipidus. <i>Korean Journal of Internal Medicine</i> , 2014 , 29, 246-9	2.5	12
175	Clinical features and treatment of collecting duct carcinoma of the kidney from the korean cancer study group genitourinary and gynecology cancer committee. <i>Cancer Research and Treatment</i> , 2014 , 46, 141-7	5.2	11
174	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22164-e22164	2.2	
173	Everolimus-associated pneumonitis in Asian metastatic renal cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15596-e15596	2.2	
172	A phase 2 study of trastuzumab in combination with S-1 and cisplatin in first-line human epidermal growth factor receptor (HER)-2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 127-127	2.2	
171	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013 , 21, 1751-9	3.9	27
170	Application of the adjuvant! Online model to Korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. <i>Annals of Surgical Oncology</i> , 2013 , 20, 2615-24	3.1	17
169	Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation. <i>Radiotherapy and Oncology</i> , 2013 , 108, 72-7	5.3	18

168	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013 , 8, 203-209	5	45
167	Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. <i>Investigational New Drugs</i> , 2013 , 31, 1602-8	4.3	31
166	Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. <i>BMC Cancer</i> , 2013 , 13, 394	4.8	22
165	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , 2013 , 31, 1-13	4.3	10
164	Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program. <i>Urology</i> , 2013 , 81, 143-9	1.6	15
163	Characterization of naturally Epstein-Barr virus-infected gastric carcinoma cell line YCCEL1. <i>Journal of General Virology</i> , 2013 , 94, 497-506	4.9	41
162	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , 2013 , 107, 613-8	2.8	17
161	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 825-35	3.5	53
160	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 853-60	3.5	5
159	Difference of interferon- α and interferon- β in melanoma growth and lymph node metastasis in mice. <i>Melanoma Research</i> , 2013 , 23, 114-24	3.3	16
158	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. <i>Journal of Clinical Oncology</i> , 2013 , 31, 731-7	2.2	133
157	Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. <i>Gut</i> , 2013 , 62, 22-33	19.2	75
156	Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013 , 43, 996-1003	2.8	23
155	Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer. <i>Journal of Radiation Research</i> , 2013 , 54, 52-60	2.4	9
154	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 265-72	1.9	8
153	Telomerase- and angiogenesis-related gene responses to irradiation in human umbilical vein endothelial cells. <i>International Journal of Molecular Medicine</i> , 2013 , 31, 1202-8	4.4	7
152	PIK3CA mutations in hepatocellular carcinoma in Korea. <i>Yonsei Medical Journal</i> , 2013 , 54, 883-7	3	2
151	The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma. <i>Yonsei Medical Journal</i> , 2013 , 54, 865-74	3	12

150	Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. <i>Yonsei Medical Journal</i> , 2013 , 54, 854-64	3	9
149	Efficacy and toxicity of sunitinib in renal insufficiency patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e15573-e15573	2.2	
148	Differential expression patterns of MMPs and their role in the invasion of epithelial premalignant tumors and invasive cutaneous squamous cell carcinoma. <i>Experimental and Molecular Pathology</i> , 2012 , 92, 236-42	4.4	25
147	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. <i>Cancer</i> , 2012 , 118, 729-39	6.4	114
146	Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 635-42	2.5	20
145	A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. <i>Investigational New Drugs</i> , 2012 , 30, 357-63	4.3	5
144	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , 2012 , 30, 672-80	4.3	14
143	A new prognostic index model using meta-analysis in early-stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2012 , 126, 357-63	4.9	5
142	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. <i>Gut</i> , 2012 , 61, 673-84	19.2	476
141	Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. <i>Radiotherapy and Oncology</i> , 2012 , 104, 367-73	5.3	46
140	An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012 , 48, 324-32	7.5	70
139	A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , 2012 , 48, 518-26	7.5	98
138	Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. <i>BMC Genomics</i> , 2012 , 13, 348	4.5	80
137	Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea. <i>BMC Cancer</i> , 2012 , 12, 322	4.8	14
136	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , 2012 , 12, 471	4.8	1
135	Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. <i>Nature Genetics</i> , 2012 , 44, 570-4	36.3	486
134	EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. <i>Yonsei Medical Journal</i> , 2012 , 53, 1128-35	3	19
133	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. <i>Investigational New Drugs</i> , 2012 , 30, 1501-10	4.3	17

132	Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. <i>Oncology Letters</i> , 2012 , 3, 699-703.	3.6	10
131	Phase II trial of tesetaxel, an oral taxane, as second-line therapy for patients with advanced gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4077-4077	2.2	1
130	Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy. <i>PLoS ONE</i> , 2012 , 7, e45127	3.7	13
129	Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. <i>Cancer Research and Treatment</i> , 2012 , 44, 43-9	5.2	13
128	Methylation status of lamin A/C in gastric cancer cell lines. <i>Hepato-Gastroenterology</i> , 2012 , 59, 1313-8		3
127	Safety and efficacy of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC) who failed previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: A subanalysis of REACT.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15064-e15064	2.2	1
126	An in-depth multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) that do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4536-4536	2.2	
125	Comparison of S-1 and cisplatin combination versus S-1 adjuvant chemotherapy for advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14652-e14652	2.2	
124	Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4538-4538	2.2	
123	The efficacy and toxicity of 3-weekly TS-1 containing chemotherapy in patients with unresectable advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14580-e14580	2.2	
122	Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. <i>Gastroenterology</i> , 2011 , 141, 476-85, 485.e1-11	13.3	244
121	CD44-SLC1A2 gene fusions in gastric cancer. <i>Science Translational Medicine</i> , 2011 , 3, 77ra30	17.5	43
120	Systematic analyses of genes associated with radiosensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor. <i>Journal of Radiation Research</i> , 2011 , 52, 752-65	2.4	6
119	Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 2011 , 22, 801-10	2.4	13
118	Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. <i>Oncology Reports</i> , 2011 , 25, 717-27	3.5	11
117	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. <i>Experimental and Therapeutic Medicine</i> , 2011 , 2, 685-693	2.1	28
116	Treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 258-69	1.9	9
115	Prevalence and associated factors of psychological distress among Korean cancer patients. <i>General Hospital Psychiatry</i> , 2011 , 33, 246-52	5.6	28

114	Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2011 , 125, 55-63	4.4	45
113	Brain metastases from colorectal carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 49-55	4.8	65
112	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 991-9	3.5	4
111	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. <i>Cancer</i> , 2011 , 117, 2050-7	6.4	38
110	Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3968-76	2.7	844
109	A prognostic model to predict clinical outcome in gastric cancer patients with bone metastasis. <i>Oncology</i> , 2011 , 80, 142-50	3.6	32
108	Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. <i>Oncology</i> , 2011 , 80, 395-405	3.6	45
107	Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity. <i>Oncology</i> , 2011 , 80, 107-17	3.6	10
106	Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. <i>Oncology</i> , 2011 , 81, 175-83	3.6	16
105	Advanced detection of recent changing trends in gastric cancer survival: up-to-date comparison by period analysis. <i>Japanese Journal of Clinical Oncology</i> , 2011 , 41, 1344-50	2.8	13
104	A densely interconnected genome-wide network of microRNAs and oncogenic pathways revealed using gene expression signatures. <i>PLoS Genetics</i> , 2011 , 7, e1002415	6	26
103	Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. <i>Cancer Science</i> , 2010 , 101, 2200-6	6.9	19
102	Green tea consumption and stomach cancer risk: a meta-analysis. <i>Epidemiology and Health</i> , 2010 , 32, e2010001	5.6	26
101	Kidney Cancer Working Group report. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40 Suppl 1, i51-56	2.8	43
100	Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma. <i>International Journal of Hyperthermia</i> , 2010 , 26, 305-15	3.7	40
99	Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m ² bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40, 29-35	2.8	2
98	Integration of Microarray Datasets 2010 , 325-345		
97	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , 2010 , 288, 124-32	9.9	30

96	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010 , 95, 303-7	5.3	21
95	A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 56-60	2.7	2
94	The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. <i>Annals of Surgical Oncology</i> , 2010 , 17, 3259-68	3.1	38
93	Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 797-805	3.5	20
92	Adenocarcinoma of the small bowel at a single Korean institute: management and prognosticators. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 387-94	4.9	31
91	The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 517-26	4.9	24
90	Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010 , 136, 1901-13	4.9	20
89	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010 , 28, 650-8	4.3	15
88	Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2010 , 201, 73-80		16
87	Wernicke's encephalopathy in advanced gastric cancer. <i>Cancer Research and Treatment</i> , 2010 , 42, 77-81	5.2	11
86	Novel sunitinib strategy in metastatic renal cell carcinoma on hemodialysis: intermittent dose of sunitinib after hemodialysis. <i>Cancer Research and Treatment</i> , 2010 , 42, 180-4	5.2	9
85	Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. <i>Cancer Research and Treatment</i> , 2010 , 42, 217-24	5.2	20
84	Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. <i>Yonsei Medical Journal</i> , 2009 , 50, 296-9	3	2
83	A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status. <i>Oncology</i> , 2009 , 77, 349-57	3.6	5
82	Oncogenic pathway combinations predict clinical prognosis in gastric cancer. <i>PLoS Genetics</i> , 2009 , 5, e1000676	2.79	
81	A weighted sample size for microarray datasets that considers the variability of variance and multiplicity. <i>Journal of Bioscience and Bioengineering</i> , 2009 , 108, 252-8	3.3	6
80	The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer. <i>Journal of Surgical Oncology</i> , 2009 , 99, 275-80	2.8	42
79	Increments of alpha-dystroglycan expression in liver metastasis correlate with poor survival in gastric cancer. <i>Journal of Surgical Oncology</i> , 2009 , 100, 459-65	2.8	7

78	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 919-27	3.5	5
77	Effect of being overweight on postoperative morbidity and long-term surgical outcomes in proximal gastric carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009 , 24, 475-9	4	24
76	Prediction of recurrence of early gastric cancer after curative resection. <i>Annals of Surgical Oncology</i> , 2009 , 16, 1896-902	3.1	68
75	G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. <i>Cancer Letters</i> , 2009 , 277, 155-63	9.9	12
74	Subtelomeric DNA methylation and telomere length in human cancer cells. <i>Cancer Letters</i> , 2009 , 281, 82-91	9.9	14
73	In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. <i>Genomics</i> , 2009 , 93, 52-61	4.3	13
72	Identification of significant regional genetic variations using continuous CNV values in aCGH data. <i>Genomics</i> , 2009 , 94, 317-23	4.3	3
71	Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. <i>International Journal of Oncology</i> , 2009 , 34, 837-46	1	2
70	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , 2009 , 34, 787-96	1	1
69	Changes of telomerase activity by alternative splicing of full-length and beta variants of hTERT in breast cancer patients. <i>Oncology Research</i> , 2009 , 18, 213-20	4.8	15
68	Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. <i>Cancer Research and Treatment</i> , 2009 , 41, 67-72	5.2	57
67	Prognosis of pN3 stage gastric cancer. <i>Cancer Research and Treatment</i> , 2009 , 41, 73-9	5.2	16
66	Clinical value of ezrin expression in primary osteosarcoma. <i>Cancer Research and Treatment</i> , 2009 , 41, 138-44	5.2	33
65	Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. <i>Cancer Research and Treatment</i> , 2009 , 41, 196-204	5.2	21
64	Aberrant DNA Methylation in Childhood Acute Lymphoblastic Leukemia as a Potential Biomarker Reflecting Disease Status.. <i>Blood</i> , 2009 , 114, 2637-2637	2.2	
63	Improving the prediction accuracy in classification using the combined data sets by ranks of gene expressions. <i>BMC Bioinformatics</i> , 2008 , 9, 283	3.6	14
62	SNPAnalyzer 2.0: a web-based integrated workbench for linkage disequilibrium analysis and association analysis. <i>BMC Bioinformatics</i> , 2008 , 9, 290	3.6	78
61	Variation of the 3Ntelomeric overhang lengths in human cells. <i>Cancer Letters</i> , 2008 , 264, 107-18	9.9	10

60	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , 2008 , 270, 269-76	9.9	5
59	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2008 , 87, 361-6	5.3	8
58	Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma. <i>Molecular Cancer Research</i> , 2008 , 6, 1554-66	6.6	26
57	Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. <i>Cancer Research</i> , 2008 , 68, 4277-86	10.1	74
56	Cyclooxygenase-2 expression in pretreatment biopsy as a predictor of tumor responses after preoperative chemoradiation in rectal cancer. <i>Archives of Surgery</i> , 2008 , 143, 1091-7; discussion 1097		17
55	OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. <i>PLoS ONE</i> , 2008 , 3, e2990	3.7	84
54	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 75-81	3.5	9
53	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 157-65	3.5	11
52	A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 315-21	3.5	15
51	Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 108, 241-50	4.4	425
50	S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. <i>Korean Journal of Internal Medicine</i> , 2008 , 23, 37-41	2.5	
49	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007 , 46, 547-9	3.2	0
48	Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. <i>Yonsei Medical Journal</i> , 2007 , 48, 171-5	3	12
47	Whole genome analysis for liver metastasis gene signatures in colorectal cancer. <i>International Journal of Cancer</i> , 2007 , 121, 2005-12	7.5	180
46	Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. <i>Journal of Surgical Oncology</i> , 2007 , 95, 461-8	2.8	67
45	A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 204-10	4	54
44	Novel and simple transformation algorithm for combining microarray data sets. <i>BMC Bioinformatics</i> , 2007 , 8, 218	3.6	9
43	Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization. <i>BMC Genomics</i> , 2007 , 8, 305	4.5	23

42	Gastrointestinal stromal tumor of the rectum: an analysis of seven cases. <i>Surgery Today</i> , 2007 , 37, 455-9	3	24
41	Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single Korean institute. <i>Annals of Surgical Oncology</i> , 2007 , 14, 2730-7	3.1	56
40	Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 104, 31-7	4.4	2
39	A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2007 , 59, 313-20	3.5	7
38	Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. <i>Oncologist</i> , 2007 , 12, 543-54	5.7	31
37	An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. <i>Oncologist</i> , 2007 , 12, 622-30	5.7	46
36	Bilateral breast cancer: differential diagnosis using histological and biological parameters. <i>Japanese Journal of Clinical Oncology</i> , 2007 , 37, 487-92	2.8	26
35	Role of 18F-fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. <i>Oncology</i> , 2007 , 72 Suppl 1, 104-10	3.6	89
34	Identification of genes with correlated patterns of variations in DNA copy number and gene expression level in gastric cancer. <i>Genomics</i> , 2007 , 89, 451-9	4.3	51
33	Molecular basis of the differences between normal and tumor tissues of gastric cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2007 , 1772, 1033-40	6.9	33
32	An attempt for combining microarray data sets by adjusting gene expressions. <i>Cancer Research and Treatment</i> , 2007 , 39, 74-81	5.2	4
31	A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report. <i>Cancer Research and Treatment</i> , 2007 , 39, 134-7	5.2	4
30	A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer. <i>Oncology</i> , 2006 , 70, 63-70	3.6	15
29	Intermediate dose 5-fluorouracil-induced encephalopathy. <i>Japanese Journal of Clinical Oncology</i> , 2006 , 36, 55-9	2.8	42
28	Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. <i>Clinical Cancer Research</i> , 2006 , 12, 6351-8	12.9	75
27	Statistical Issues in the Search for Biomarkers of Colorectal Cancer Using Microarray Experiments. <i>Wiley Series in Probability and Statistics</i> , 2006 , 333-343	1.3	1
26	Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 429-38	1.9	45
25	Induction of cell apoptosis in non-small cell lung cancer cells by cyclin A1 small interfering RNA. <i>Cancer Science</i> , 2006 , 97, 1082-92	6.9	14

24	Long-term survival after surgical resection for liver metastasis from gastric cancer: two case reports. <i>Cancer Research and Treatment</i> , 2006 , 38, 184-8	5.2	1
23	Systematic analysis of cDNA microarray-based CGH. <i>International Journal of Molecular Medicine</i> , 2006 , 17, 261-7	4.4	10
22	Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005 , 90, 215-21	4.4	54
21	Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. <i>Breast Cancer Research and Treatment</i> , 2005 , 93, 227-36	4.4	30
20	Clinical Implication of Bone Marrow Angiogenesis in Childhood Acute Lymphocytic Leukemia.. <i>Blood</i> , 2005 , 106, 1455-1455	2.2	
19	Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. <i>Clinical Cancer Research</i> , 2005 , 11, 79-86	12.9	23
18	Gene copy number change events at chromosome 20 and their association with recurrence in gastric cancer patients. <i>Clinical Cancer Research</i> , 2005 , 11, 612-20	12.9	31
17	Quantitative detection of telomerase activity by real-time TRAP assay in the body fluids of cancer patients. <i>International Journal of Molecular Medicine</i> , 2005 , 16, 857-63	4.4	4
16	Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1857-64	1.9	14
15	Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. <i>Cancer Letters</i> , 2004 , 214, 215-24	9.9	59
14	Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. <i>European Urology</i> , 2003 , 44, 560-6	10.2	70
13	Biological phenotype determination with ex vivo model in gastric cancer for matrix-metalloproteinase inhibitor treatment. <i>International Journal of Molecular Medicine</i> , 2002 , 10, 251-4	4.4	1
12	Correlation of tissue and blood plasminogen activation system in breast cancer. <i>Cancer Letters</i> , 2000 , 150, 137-45	9.9	20
11	Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1998 , 49, 41-50	4.4	11
10	An unusual case of gastric carcinoma with synchronous non-Hodgkin's lymphoma. <i>Yonsei Medical Journal</i> , 1998 , 39, 463-7	3	1
9	Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. <i>Yonsei Medical Journal</i> , 1998 , 39, 27-36	3	18
8	Relationship between p53 overexpression and gastric cancer progression. <i>Oncology</i> , 1997 , 54, 166-70	3.6	17
7	Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. <i>Cancer Letters</i> , 1997 , 118, 37-46	9.9	14

6	Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. <i>Breast Cancer Research and Treatment</i> , 1997 , 43, 175-81	4.4	36
5	P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997 , 42, 65-72	4.4	38
4	Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 484-9	2.7	10
3	A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 569-72	2.7	11
2	Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. <i>Oncology</i> , 1996 , 53, 192-7	3.6	27
1	Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. <i>Clinical and Experimental Metastasis</i> , 1996 , 14, 512-9	4.7	39